万邦德：在研的小分子多肽新药，已取得良好的前期数据，有计划推进临床转化

Group 1 - The company is developing a small molecule peptide drug for obesity and diabetes, currently in the preclinical stage with promising preliminary data and plans for clinical transition [2] - The drug's mechanism and target differ from GLP-1 drugs like Semaglutide, showing significant weight loss efficiency in diabetic obese mouse studies compared to Semaglutide [2] - The drug not only aids in weight loss and fat burning but also reduces muscle loss, lowers blood sugar, has anti-inflammatory effects, and improves various metabolic indicators [2] Group 2 - The company will fulfill its information disclosure obligations regarding any external collaborations based on progress, with specific announcements to follow [2]